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Abstract: Diet is a key component of care during chronic kidney disease (CKD). Nutritional
interventions, and, specifically, a restricted protein diet has been under debate for decades. In order
to reduce the risk of nutritional disorders in very-low protein diets (VLDP), supplementation by
nitrogen-free ketoacid analogues (KAs) have been proposed. The aim of this review is to summarize
the potential effects of this dietary therapy on renal function, uremic toxins levels, and nutritional
and metabolic parameters and propose future directions. The purpose of this paper is also to
select all experimental and randomized clinical studies (RCTs) that have compared VLDP + KA
to normal diet or/and low protein diet (LPD). We reviewed the SCOPUS, WEB of SCIENCES,
CENTRAL, and PUBMED databases from their inception to 1 January, 2019. Following duplicate
removal and application of exclusion criteria, 23 RCTs and 12 experimental studies were included.
LPD/VLPD + KAs appear nutritionally safe even if how muscle protein metabolism adapts to an
LPD/VLPD + KAs is still largely unknown. VLPD + KAs seem to reduce uremic toxins production
but the impact on intestinal microbiota remains unexplored. All studies observed a reduction of
acidosis, phosphorus, and possibly sodium intake, while still providing adequate calcium intake.
The impact of this diet on carbohydrate and bone parameters are only preliminary and need to be
confirmed with RCTs. The Modification of Diet in Renal Disease study, the largest RCTs, failed to
demonstrate a benefit in the primary outcome of the decline rate for the glomerular filtration rate.
However, the design of this study was challenged and data were subsequently reanalyzed. However,
when adherent patients were selected, with a rapid rate of progression and a long-term follow up,
more recent meta-analysis and RCTs suggest that these diets can reduce the loss of the glomerular
filtration rate in addition to the beneficial effects of renin-angiotensin-aldosterone system (RAAS)
inhibitors. The current evidence suggests that KAs supplemented LPD diets should be included as
part of the clinical recommendations for both the nutritional prevention and metabolic management
of CKD. More research is needed to examine the effectiveness of KAs especially on uremic toxins.
A reflection about the dose and composition of the KAs supplement, the cost-effective features, and
their indication to reduce the frequency of dialysis needs to be completed.
Keywords: chronic kidney disease; low protein diet; ketoacid analogues; intestinal microbiota; dialysis
1. Introduction
End-stage kidney disease (ESKD) is a condition associated with a high mortality and poor quality
of life combined with extremely high costs. Using interventions for delaying the need to start a kidney
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replacement treatment is, therefore, a major challenge. Experimentally, Brenner et al. [1] showed
that high protein intake induced marked kidney hypertrophy, which is an increase in glomerular
pressure and hyperfiltration that negatively impacts kidney function. Chronic kidney disease (CKD) is
characterized by the accumulation of a number of organic solutes called uremic toxins. Many of these
uremic toxins are produced by the degradation of dietary amino acids by intestinal microbiota and
appears to accelerate CKD progression. Based on these observations, a reduction in protein intake can
be expected to preserve renal function and reduce uremic toxicity. The main limitation of this diet is
the risk of malnutrition and cachexia.
Different dietary protein regimens have been tested: low–protein diets (LPD, 0.6 g protein/kg/day)
or very low–protein diets (VLPD: 0.3–0.4 g protein/kg/day) supplemented with essential amino acids
(EAAs) or nitrogen-free ketoacid analogues (KAs). KAs are precursors of corresponding amino acids
since they can undergo a transamination, e.g., a chemical reaction that transfers an amino group to
a ketoacid to form a new amino acid (Figure 1). This pathway is responsible for the deamination of
most amino acids. Through this conversion, KAs can be utilized in place of their respective EAAs
without providing nitrogen products while re-using available nitrogen already in excess during CKD.
If a diet does not provide enough EAAs or calories, then the nitrogen balance can become negative
and could partly induce cachexia. Therefore, administration of KAs has been proposed to improve
protein status while limiting the nitrogen burden on the body. VLDP + KAs are likely also efficient
because the calcium content of KA preparation could allow a better correction of mineral metabolism
impairment. Different compositions of KAs and EAAs have been tested, with most of them containing
four KAs (of the EAA isoleucine, leucine, phenylalanine, and valine), one hydroxyacid (of the EAA
methionine), and four amino acids considered essential in CKD (tryptophan, threonine, histidine, and
tyrosine) (Table 1).
Since the publication of the perspective by Shah et al. [2] on the role of KA supplementation in the
management of CKD, great effort was undertaken to perform randomized controlled trials (RCTs). This
review outlines the potential mechanisms of action and efficacy of KAs in renal function and metabolic
parameters with a particular emphasis on potential anabolic effects and reduction of uremic toxins
production. Our review mainly focuses on recent experimental data and RCTs. Lastly, we propose
new fields of investigation for KAs in future research.
Nutrients 2018, 10, x FOR PEER REVIEW  2 of 21 
high protein intake ind ced marked kidney hypertrophy, which is an increase in glomerular pressure 
and hyperfiltration that nega ively imp cts kidn y function. Chronic kidney disease (CKD) is 
char cterized by th  accumulation f a number of organic solutes c ll  uremic toxins. Many of these 
uremic toxins a  p oduced by the degradation of dietary amino acids by ntestinal microbiota and 
appears to accelera e CKD progression. Based on these observations, a reduction in protein intake can 
be expected o preserve renal function and reduce ur mic toxicity. The main limitation of this diet is the 
risk of malnutri io  and cachexia.  
Different di tary protein regimens have been tested: low–protein diets (LPD, 0.6 g protein/kg/day) 
or very low–protein diets (VLPD: 0.3–0.4 g protein/kg/day) supplemented with essent al amino acids 
(EAAs) or nitrogen-fr e ketoacid analo es (KAs). KAs are precursors of corresponding amino acids 
since they can undergo a transamination, e.g., a chemical reaction that transfers an amino group to a 
ke oacid to form a ew amino acid (Figur  1). This pathway is respo sibl  for th  deamination of most 
amino acids. Through this c nversion, KAs can be utilized i  plac  of their respective EAAs w thout 
providing nitroge  products while re-using available nitrogen already in xcess during CKD. If a diet 
does ot provide enough EAAs or calories, then the nitrogen balance can become neg tive and could 
partly induce cachexia. There ore, administration of KAs h s been proposed to i prove protein tatus 
while limiting th  nitrogen burde  on the body. VLDP + KAs are likely also efficient because the calcium 
content of KA preparati n could allow a bett r correction of mineral metabolism impairment. Different 
comp s tions of KAs and EAAs have been tested, with most of them containing four KAs (of the EAA 
isoleucine, leucine, phenylalanine, and valine), one hydroxyacid (of the EAA methionine), and four 
amino acids considered essential in CKD (tryptop an, threonine, histidine, and tyrosine) (Table 1). 
Since the publication of the perspective by Shah et al. [2] on the role f KA supplementation in the 
management of CKD, great effort wa  undertake  to p rform randomized controlled trials (RCTs). This 
review outlines the po enti l mechanisms of action and efficacy of KAs in renal fu ction and metabolic 
arameters with a particular emphasi   potential anabolic effects and reduction of uremic toxins 
production. Our review mainly focuses on recent experimental data and RCTs. Lastly, we propose new 
fields of investigation for KAs in future research. 
. 
Figure 1. Amino-acid and transamination of ketoacid analogues of amino acids in order to synthesize 
protein. 
  
Figure 1. Amino-acid and transamination of ketoacid analogues of amino acids in order to
synthesize protein.
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Table 1. Ketoacid analogues composition.
Component Name mg/pill
Ca-Keto-dl-isoleucine 67
Ca-Ketoeucine 101
Ca-Ketophénylalanine 68
Ca-Ketovaline 86
Ca-Hydroxy-dl-methionine 59
l-Lysine monoacetate 105
l-Threonine 53
l-Tryptophan 23
l-Histidine 38
l-Tyrosine 30
Ca: calcium.
2. Methods
We performed a literature search of trials in SCOPUS, WEB of SCIENCES, CENTRAL, and
PUBMED databases from their inception to 1 January, 2019 initially without a language restriction.
The search strategy used the terms renal or ESRD or end stage renal disease or kidney or CKD or
chronic kidney disease and ketoacids or keto analogs or very low protein diet. Titles and abstracts of
publications returned from the search were screened for relevance by three authors (L.K., M.C.d.O., and
D.F). Clinical studies were included if (i) full text was available in English, (ii) focused on a randomized
controlled trial, and (iii) investigated the effect of KAs in non-dialysis CKD patients of any age.
Abstracts, case reports, narrative reviews, editorials, letters, and practice guidelines were excluded.
We identified 13,132 potentially relevant references from the search (12,453 records without duplicates,
Supplementary Figure S1). After title and abstract screening, 140 full-text articles were considered for
inclusion. Twenty-three full-text studies were selected in order to analyze the potential effects of KAs.
For experimental studies, we performed a literature search on the PubMed database from inception to
1 January, 2019. We only kept experimental studies, which used a control group.
3. Potential Benefit of Ketoacid Analogues
Do we have evidence in CKD of specific KAs actions on the reduction of kidney disease-associated
comorbidity? New emerging studies suggest that restricted VLDP + KAs may improve renal function
and nutritional status, while preventing hyperparathyroidism, insulin resistance, and accumulation of
uremic retention solutes (URS), as summarized in Figure 2. The main concern about the interpretation
of the literature is the fact that KAs are not given solely but in association with other EAAs and under
LPD/VLPD condition. In particular, we do not know if a supplementation of KA alone without low
protein diets has any benefit on metabolic disturbances related to CKD. Few studies [3–7] compared
KAs supplementation with the same protein restriction and it is difficult to decipher if “KAs effects” are
solely the consequence of a decrease of protein intake or if they act specifically. Another interrogation
is the reproducibility of the diet composition in different groups. The composition of fibers, acid load,
or sodium is difficult to assess and frequently not specified in dietary surveys, which can influence
the results. In order to have a more detailed picture of the effects of KAs during CKD, the main
experimental trials and RCTs have been summarized in Tables 2 and 3.
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Table 2. Animal studies that examined the effects of VLPD/LPD supplemented with ketoacid analogues on various endpoints.
Study Models Diet Intervention Follow-Up Results (LPD vs. VLDP/LPD + KAs)
Wang et al., 2018 [8] 5/6 nephrectomy rats
NPD: 22% protein
vs.
LPD: 6% protein
vs.
LPD + KAs: 5% protein plus 1% KA
24 weeks
↓muscle atrophy
↑ activities of mitochondrial electron transport chain complexes and
mitochondrial respiration,
↓muscle oxidative damage
↑body weight
Liu et al., 2018 [9] KKAy mice, an early type 2DN model
NPD: 22% protein
vs.
LPD: 6% protein
vs.
LPD + KAs: 5% protein plus 1% KA
12 weeks
↓ proteinuria
↓mesangial proliferation and oxidative stress
↑ serum albumin and body weight
No difference in creatinine and GFR
Zhang et al., 2016 [10] 3/4 nephrectomy rats
NPD: 18% protein
vs.
LPD: 6% protein
vs.
LPD + KAs: 5% protein plus 1% KA
12 weeks
↓ proteinuria
↓ intrarenal RAS activation.
↓ transforming growth factor-β1 in the mesangial cells
Zhang et al., 2015 [11] 5/6 nephrectomy rats
NPD: 11 g/kg/day protein
vs.
LPD: 3 g/kg/day protein
vs.
LPD + KAs: 3 g/kg/day protein which
including 5% protein plus 1% KA
24 weeks
↑ body weight, gastrocnemius muscle mass
↓ autophagy marker in muscle
No difference of inflammation markers
Wang et al., 2014 [12] 5/6 nephrectomy rats
NPD: 22% protein
vs.
LPD: 6% protein
vs.
LPD + KAs: 5% protein plus 1% KA
24 weeks
↑improved protein synthesis and increased related mediators such as
phosphorylated Akt in the muscle
↓ protein degradation and proteasome activity in the muscle
Gao et al., 2010 [13] 5/6 Nephrectomy rats
NPD: 22% protein
vs.
LPD: 6% protein
vs.
LPD + KAs: 5% protein plus 1% KA
24 weeks
↓ proteinuria, glomerular sclerosis, and tubulointerstitial fibrosis
↑renal function
↑ body weight and albumin
↓ lipid and protein oxidative products
Gao et al., 2011 [14] 5/6 Nephrectomy rats
NPD: 22% protein
vs.
LPD: 6% protein
vs.
LPD + KAs: 5% protein plus 1% KA
6 months
↑ body weight and albumin
↑ Kruppel-like factor-15, a transcription factor shown to
reduce fibrosis
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Table 2. Cont.
Study Models Diet Intervention Follow-Up Results (LPD vs. VLDP/LPD + KAs)
Maniar et al., 1992 [15] 5/6 Nephrectomy rats
NPD: 16% casein
vs.
LPD + EAA: 6% casein + EAA
vs.
LPD + KAs: 6% casein + KA
3 months
No difference on body weight
No difference on proteinuria vs. LDP + EAA but reduction vs. NPD
↓ creatinemia, proteinuria, glomerular sclerosis, and tubulointerstitial
fibrosis vs. NPD but no difference vs. LPD + EAA
↑survival vs. NPD but no difference vs. LPD + EAA
Laouari et al., 1991 [16] 5/6 Nephrectomy rats
NPD: 12% casein
vs.
LPD + EAAs: 5% casein + EAA
vs.
LPD + KAs: 5% casein + KA
↓Appetite and growth
No increase in BCAAs
Benjelloun et al., 1993 [17]
Rats with after a single
5 mg/kg intravenous injection
of Adriamycin: a model of
induces glomerular damage
in glomerulonephritis.
NPD: 21% protein
vs.
LPD + KAs: 6% protein plus KA
15 days
↓ proteinuria
↓ glycosaminoglycan excretion
and glomerular glycosaminoglycan contents
Barsotti et al; 1988 [18] 5/6 Nephrectomy rats
NPD: 20.5% protein
vs.
LPD + KAs: 3.3% protein plus 7.5% KA
3 months
↑survival
↑ GFR
↓ proteinuria and histological damage of kidney
No difference in body weight and albuminuria
Meisinger et al., 1987 [19] 5/6 Nephrectomy rats
LPD: 8% protein
vs.
LPD + KAs: 8% protein plus KA
3 months ↓ proteinuria
NPD: normal protein diet. HPD: high protein diet. GFR: estimated Glomerular Filtration Rate. LPD: Low protein diet. KAs: ketoacid analogues. EAAs: essential amino acids. BCAAs:
branched-chain amino acids; RAS: renin angiotensin system; NPD: normal protein diet.
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Table 3. Main RCTs that examined the effects of LPD or VLDP/LPD supplemented with ketoacid analogues on various endpoints in non-dialysis patients with eDFG
under 60 mL/min/1.73 m2.
Study Design of Study Diet Follow-Up Results Comments
Milovanova et al., 2018 [3]
RCT
n = 42 in LPD + KA vs. LPD n = 37
Non-diabetic CKD 3B–4
LPD (0.6 g/kg of body weight/day, comprising 0.3 g of
vegetable protein and 0.3 g of animal protein, phosphorus
content≤ 800 mg/day and calories: 34–35 kcal/kg/day) vs.
LPD + KA: 0.6 g/kg of body weight/day
14 months
↑ eGFR (29.1 L/min/1.73 m2 vs. 26.6)
↓SBP
↑BMI and muscle body mass
NO change in albumin levels
No change in lipids parameters
↓ phosphate, FGF23, and PTH levels ↑Klotho
levels and phosphate binder uses
↑bicarbonates levels
Similar protein intake in
both group
Long follow up
Di Iorio et al., 2018 [20]
RCT, crossover trial
CKD stages 3B–4
Group A1: 3 months of FD, 6 months of
VLPD + KA, 3 months of FD and
6 months of MD
Group B: 3 months of FD, 6 months of
MD, 3 months of FD and 6 months of
VLPD + KA.
n = 30 in each group
FD: proteins 1 g/kg body weight (bw)/day (animal proteins
50–70 g/day, vegetal proteins 15–20 g/day), energy 30–35
kcal/bw/day, calcium (Ca) 1.1–1.3 g/day, phosphorus (P)
1.2–1.5 g/day, sodium (Na) 6 g/day and potassium (K)
2–4 g/day.
MD: proteins 0.7–0.8 g/kg bw/day (animal proteins
30–40 g/day, vegetal proteins 40–50 g/day), energy
30–35 kcal/bw/day, Ca 1.1–1.3 g/day, P 1.2–1.5 g/day, Na
2.5–3 g/day and K 2–4 g/day.
VLPD + KA: proteins 0.3–0.5 g/kg bw/day (animal proteins
0 g/day, vegetal proteins 30–40 g/day), energy 30–35
kcal/bw/day, Ca 1.1–1.3 g/day, P 0.6–0.8 g/day, Na 6 g/day, K
2–4 g/day plus a mixture of KA
6 months
↓ SBP
No change in creatinuria
↓proteinuria
↓ phosphate, FGF23, and PTH levels
↑bicarbonates levels
↑Hg levels
↓protein carbamylation
Sodium intake and phosphore
intake was reduce in VLDP +
KA group
Garneata et al., 2016 [21]
RCT
CKD stage 4–5,
proteinuria < 1 g/24 h
n = 207
LPD = 0.6 g protein/kg per day
vs.
VLPD + KA = vegetarian diet, 0.3 g protein/kg per day + KA
15 months
↓ RRT initiation or a >50% reduction in the
initial GFR (13% in KA+LDP vs. 42% in LPD
reached the primary composite efficacy point
i.e., RRT initiation or a >50% reduction in the
initial GFR)
↓CRP
↑bicarbonates levels
↓uric acid
↓ phosphate, FGF23 and PTH levels and
phosphate binder uses
No difference in proteinuria
No difference of death and CV events
No difference of albumin, BMI
No change in lipids parameters
Long follow up
Large effective
Only 14% of patients screened
was included
Di Iorio et al., 2012 [22]
RCT, crossover trial
eGFR < 55 and > 20 mL/min/1.73 m2
Group A: VLDP + KA during the first
week and LPD during the second week
Group B: LPD during the first week and
a VLPD + KA during the second week.
n = 16 in each group
LPD = 0.6 g protein/kg per day
vs. VLPD + KA = 0.3 g protein/kg per day + KA 1 week
↓ phosphate (−12%), FGF23 (−33.5)
No change on calcium
a post hoc of this study, ↓ indoxyl sulfate [23]
↑bicarbonates levels
Short exposition
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Table 3. Cont.
Study Design of Study Diet Follow-Up Results Comments
Di Iorio et al., 2009 [24]
RCT, crossover trial
eGFR < 55 and > 20 mL/min
Group A: VLDP + KA during 6 month
and a LPD during 6 month
Group B: LPD during 6 month and
a VLDP + KA during 6 month.
n = 16 in each group 32 patients
LPD = 0.6 g protein/kg per day
vs.
VLPD + KA = 0.3 g protein/kg per day + KA
6 months ↓proteinuria and AGE
Open label
Phosphor intake was different
and lower in VLDP+ KA
Menon et al., 2009 [25]
Post hoc study of MDRD study B
CKD stage 4 nondiabetic
n = 255
LPD = 0.6 g protein/kg per day
vs.
VLPD + KA = 0.3 g protein/kg per day + KA
10.2 years No delay progression to kidney failure↑the risk of death.
Long follow up without
intervention -Observance and
protein intake was not
monitored during the follow up
Teplan et al., 2008 [4]
RCT, double-blind placebo
CKD stage 4
n = 111
LDP: 0.6 g protein/kg per day
vs.
LPD + KA: 0.6 g protein/kg per day + KA
36 months
↓ADMA
↓ BMI and visceral body fat in obese patients
↓proteinuria
↓ glycated hemoglobin
↓LDL-cholesterol
Mean BMI was > 30 kg/m2 at
the inclusion
Long follow up
No difference of protein intake
Using a placebo
Mircescu et al., 2007 [26]
RCT
eGFR <30 mL/min/1.73 m2, nondiabetic
n = 53
VLPD + KA =0.3 g/kg vegetable proteins + KA
vs.
LPD =0.6 g/kg/d)
48 weeks
↑bicarbonates levels
↑calcium levels and ↓ phosphate
lower percentages of patients in group I
required renal replacement therapy initiation
(4% vs. 27%).
No change of rate of eGFR and proteinuria
No change in SBP
Open label
Gennari et al., 2006 [27]
Post hoc study of MDRD study
RCT
CKD stage 4–5
n = 255
LPD = 0.6 g protein/kg per day
vs.
VLPD + KA = 0.3 g protein/kg per day + KA
2,2 years No significant effect of diet on serum totalCO2 was seen
Menon et al., 2005 [28]
Post oc study of MDRD study
RCT
CKD stage 4–5
n = 255
LPD = 0.6 g protein/kg per day
vs.
VLPD + KA = 0.3 g protein/kg per day + KA
2.2 years ↓ homocysteinemia by 24% at 1 year
Feiten et al., 2005 [29]
RCT
n = 24
eGFR <25 mL/min
VLPD + KA = 0.3 g/kg vegetable proteins + KA
vs.
LPD = 0.6 g/kg/d
4 months
↑bicarbonates levels
No change on calcium levels
↓ phosphate and PTH
Decrease the progression of renal decline
function of rate of eGFR
No change in lipid parameters
No change in nutritional status (BMI,
albumin)
Open label
Short time of follow up
Significant reduction in dietary
phosphorus (529 ± 109 to 373 ±
125 mg/day, p < 0.05)
Prakash et al., 2004 [30]
RCT, double-blind placebo
eGFR:28 mL/min/1.73 m2
n = 34
LPD = 0.6 g protein/kg per day + placebo
vs.
VLPD = 0.3 g protein/kg per day + KA
9 months
preserve mGFR (−2% in LDP + KA vs. −21%
in LPD)
No effect on proteinuria
No effect of BMI and albumin
Measure of GFR with
99mTc-DTPA
The placebo is problematic
because protein intake was
different between both groups.
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Table 3. Cont.
Study Design of Study Diet Follow-Up Results Comments
Teplan et al., 2003 [5]
RCT
eGFR: 22–36 mL/min/1.73 m2
n = 186
LPD 0.6 g protein/kg per day + rhuEPO + KA
vs. LPD: 0.6 g protein/kg per day + rhuEPO
vs. LPD: 0.6 g protein/kg per day
3 years
Slower progression of CKD
↓proteinuria
↓LDL-cholesterol
No change in SBP
↑albumin
↑ plasmatic leucine levels
Role of rhuEPO unclear
Insulin clearance
Di iorio et al., 2003 [31]
RCT
eGFR: < or =25 mL/min/1.73 m2
n = 10 in each group
LPD = 0.6 g protein/kg per day
vs.
VLPD = 0.3 g protein/kg per day + KA
2 years
No difference on hemoglobin
↓ EPO dose
↓ phosphate and PTH
No change in BMI and albumin
No difference in the rate of RRT initiation
(8 vs. 7)
Slower rate of GFR decline
(creatinine clearance)
↓SBP and 24 h NA excretion
↓LDL-cholesterol
Very few populations
Bernhard et al., 2001 [6]
RCT
CKD stage 4–5
n = 6 in each group
LPD = 0.6 g protein/kg per day
vs.
LPD + KA = 0.6 g protein/kg per day + KA
3 months
No difference could be attributed to the
ketoanalogs total body flux and
leucine oxidation
No difference on phosphorus, calcium levels
No difference on BMI and albumin
No difference in renal function
and proteinuria
No difference on bicarbonatemia
KA is metabolically safe
Short follow-up
Small effective
Malvy et al., 1999 [32]
RCT
eGFR<20 mL/min/1.73 m2
n = 50
LPD:LPD = 0.65 g protein/kg per day + Ca+
vs.
VLPD + KA = 0.3 g protein/kg per day + KA
3 months
or time to eGFR <
5 mL/min/1.73 m2
or RRT
No difference on GFR progression
↑calcium levels
↓ phosphate and PTH
No difference on lipid parameters
Kopple et al., 1997 [33]
Post hoc study of MDRD study
RCT
CKD stage 4–5
n = 255
LPD = 0.6 g protein/kg per day
vs.
VLPD + KA = 0.3 g protein/kg per day + KA
2,2 years
No difference of death and first
hospitalization
↑ albumin
↓ transferrin, body wt, percent body fat, arm
muscle area, and urine creatinine excretion
No correlation between nutritional
parameters and death or hospitalization
↓ energy intake
Levey et al., 1996 [34]
Post hoc study of MDRD study
RCT
CKD stage 4–5
n = 255
LPD = 0.6 g protein/kg per day
vs.
VLPD + KA = 0.3 g protein/kg per day + KA
2.2 years
A 0.2 g/kg/d lower achieved total protein
intake was associated with a 1.15 mL/min/yr
slower mean decline in GFR (p = 0.011),
which is equivalent to 29% of the mean
GFR decline
Reanalyze of MDRD study by
using correlations of protein
intake with a rate of decline in
GFR and time to renal failure
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Table 3. Cont.
Study Design of Study Diet Follow-Up Results Comments
Klahr et al., 1994 Study 2
[35]
RCT
CKD stage 4–5
n = 255
LPD = 0.6 g protein/kg per day
vs.
VLPD + KA = 0.3 g protein/kg per day + KA
27 months
Marginally slower eGFR decline (−19% in
LPD vs. 12% in VLDP + KA, p 0.067)
No significant interactions between
blood-pressure interventions and the rate of
decline in eGFR
No difference on albumin
No difference in proteinuria
-Large RCT study
-Good adherence of diet
-Measured GFR with
iothalamate
Coggins et al. 1994 [36]
Feasibility phase of the MDRD Study
eGFR: 8 to 56 mL/min/1.73 m2
n = 96
25 participants were excluded
LPD = 0.6 g protein/kg per day
vs.
VLPD + KA = 0.3 g protein/kg per day + KA
6 months No difference on lipid parameters Pilot study
Lindenau et al. 1990 [37]
RCT
eGFR<15 mL/min/1.73 m2
n = 40
LPD = 0.6 g protein/kg per day + Ca+ vs. VLPD + KA =
0.4 g protein/kg per day + KA 12 months
Improvement in osteo-fibrotic as well as in
osteo-malacic changes
A calcium supplementation
was given in LPD diet as
a control for KA
Jungers et al. 1987 [38]
RCT
CKD stage 5
n = 19
LPD = 0.6 g protein/kg per day + Ca+ vs. VLPD + KA =
0.4 g protein/kg per day + KA 12 months
No difference on biochemical or
morphometric sign of de-nutrition
↑mean renal survival duration until dialysis
Small and effective
Hecking et al., 1982 [7]
RCT
Mean eGFR: 10.8 mL/min/1.73 m2
n = 15
LPD = 0.6 g protein/kg per day + Ca+ vs. LPD + KA = 0.6 g
protein/kg per day + KA or EAA or placebo
3 weeks per
periods
↓ phosphate
No difference on GFR and proteinuria
No difference on lipids parameters
No difference on albumin
Small and effective
versus the placebo
FD: Free diet. P: phosphorus. MDRD: Modification of Diet in the Renal Disease Study. eGFR: estimated Glomerular Filtration Rate. RRT: renal replacement therapy. FGF23: Fibroblast
Growth Factor 23. LPD: Low protein diet. VLDP: Very low protein diet. KA: Keto-analogues. RCT: randomized controlled trial. EAA: essential amino acids; PTH: parathyroid hormone.
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3.1. Anabolic Action of Ketoacid Analogues
CKD is associated with muscular wasting and there are some concerns about potential catabolic
and cachectic effects of LPD/VLPD. Muscle is an adaptive tissue that responds to diet, exercise, and
hormones, which may impact protein metabolism. KAs in general and ketoleucine, in particular, have
been shown to reduce muscle protein degradation [39]. However, how muscle protein metabolism
adapts to a LPD/VLPD + KAs in CKD is still an open question. Leucine kinetics studies have shown
that adaptation to dietary protein restriction involves a reduction in leucine flux and oxidation, which
leads to a more efficient use of dietary amino acids, and postprandial inhibition of protein degradation
with a reduced ureagenesis. These results were similar in CKD patients with an LPD [40] and with
a VLPD + KAs [39,41,42]. This reduction in amino acid oxidation during VLPD + KAs persisted during
a 16-month follow-up [43].
In addition, in animal models, KAs supplementation may play a protective role on muscle
atrophy [8,11,12]. In particular, in 5/6th nephrectomy rats, an LPD + KAs compared to an LPD alone
was able to suppress ubiquitin-proteasome system activation and protected skeletal muscle from
atrophy and from oxidative damage. KAs can prevent a decrease in the activity of the mitochondrial
electron transport chain complex and increase mitochondrial respiration [8,12]. LPD + KAs decreases
autophagy markers in muscle, but there was no difference in inflammation in skeletal muscle [11]. It
should be noted that the anabolic effect of KAs can be partially explained by the reduction of acid load
associated with the reduction in protein intake.
3.2. Role of Ketoacid Analogues in Intestinal Metabolism and Uremic Toxins Production
The uremic syndrome is attributed to the progressive retention of a large number of compounds
called uremic retention solutes (URS). Protein bound uremic toxins derived from gut microbiota have
emerged as a major class of URS. High levels of indoxyl sulfate (IS) (indol metabolites), p-cresyl
sulfate (PCS) (p-cresol metabolite), and trimethylamine-N-oxide (TMAO) have been associated with
an increase in cardiovascular risk and renal disease progression [44]. CKD as well as food intake have
a deep influence on gut microbiota composition with an increase of pathobionts [45] and recent data
have highlighted that modulation of intestinal microbiota appears to be an attractive strategy to reduce
URS production [44]. There are some interrogations about the fact that KAs contained a rather large
amount of tryptophan/tyrosine, which may have generated more URS. One clinical trial reported that
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a VLPD + KAs reduced IS serum levels in non-dialyzed CKD patients [23]. The reduction of URS may
be explained by the reduction of protein intake and vegetarian diet since Marzocco et al. observed that
the higher protein intake (observed during LPD compared to VLPD) was the major determinant of
IS levels [23]. In addition, Teplan et al. were able to see a decrease in asymmetric dimethylarginine
(another URS) with the same protein intake [4]. Until now, no large RCT has been performed to test
the effectiveness of KAs strategy at reducing URS and this is eagerly needed.
The impact of intestinal function and intestinal microbiota with the presence of LPD/VLPD + KAs
is unknown. Previous data suggest that the intestinal absorption of KAs is unaffected by CKD [46].
Recently, using modern mass spectrometry in germ-free mice, the serum concentration of BCAAs was
shown to be reduced whereas their fecal concentration was increased. This suggests that these amino
acids are less absorbed by the colonic mucosa but are intensely metabolized by the colonic microbiota
instead. Therefore, the impact of KAs supplementation on gut microbiota in a uremic condition must
be considered and explored.
One constant effect of VLPD/LPD + KAs treatment is the reduction of serum urea. Initially,
it was thought that an important quantity of urea was hydrolyzed during CKD and the amino-group
released from urea could aminate KAs and form new AAs. Studies indicate that the reduction in
net urea generation with LPD + KA is due to decreased amino acid degradation [41,42]. The view
that urea is simply a marker of renal dysfunction has been challenged by recent publications [47].
The microbial enzyme urease issued from the gut microbiota hydrolyzes urea and locally produces
excessive amounts of ammonia [48]. Urea and ammonia in the intestinal gut could influence the gut
microbiota composition, URS production, and disrupt the intestinal barrier, which is involved in the
pathogenesis of inflammation in CKD [48]. At disease-relevant concentrations, urea induces reactive
oxygen species (ROS) production and causes insulin resistance [49] and beta-cell dysfunction [47]
by modifying insulin signaling molecules by O-linked β-N-acetylglucosamine. In addition, urea is
able to contribute to posttranslational modification of proteins via the breakdown product cyanate
through a process called protein carbamylation, which promotes atherosclerosis and mortality during
CKD [50]. In good agreement, in a recent RCT including 60 CKD patients, the VLPD + KAs compared
to a moderate protein diet (0.7 g/kg/day) significantly decrease serum urea levels and was associated
with a reduced protein carbamylation [20].
3.3. Other Roles of Ketoacid Analogues
KA supplements have been associated with an improved bone metabolism, insulin sensitivity,
and a decrease in blood pressure. Serum bicarbonate also increased. However, the reduction in protein
intake and vegetarian diet induce a similar phenotype [51]. Therefore, the specific role of KAs on these
parameters is not clear and more studies are needed.
In a large observational study performed by Bellizzi et al. [52], patients who received LDP + KAs
had better blood pressure. In fact, there was a correlation between salt intake and blood pressure
since salt intake is reduced by the LPD. In a recent RCT, Milovanova et al. reported that LPD + KAs
improve blood pressure when compared to the control group with a similar salt and protein intake
(0.6 g/kg/day) [3]. These observed hemodynamic effects could be due to the reduction in salt intake
and possibly to an additional vasodilating effect of BCAAs-KAs supplementation.
KAs are synthesized as a calcium salt and daily provide an amount of 600 mg of calcium for
a person of 60 kg. Therefore, calcium salt may exert a direct alkaline effect and phosphorus binding.
This effect is likely amplified by a vegetarian diet. It is well-known that fruits and vegetable are an
effective intervention to correct metabolic acidosis [53,54]. However, Gennari et al. reported no effect
of diet on serum total CO2 in patients receiving a VLPD + KAs. The increase in serum bicarbonate was
related to the decrease in protein intake [27]. However, in a recent RCT with a comparable protein intake,
KAs were able to directly increase serum bicarbonate [3]. VLPD + KAs induce a reduction in serum
phosphorus only one week after initiation of treatment and this was sufficient to reduce serum FGF23
levels [22]. In a longer six-month study, VLPD + KAs was efficient to improve mineral metabolism [20].
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Lineadeau et al. [37] observed an improvement in osteo-fibrotic as well as osteo-malacic changes
on bone biopsies after 12 months of treatment with Kas. This fact is independent of calcium intake.
Indeed, the control group was supplemented in a comparable amount of calcium than the KAs group.
By contrast, Bernhard et al. [6] observed no difference on calcium, phosphorus, and serum bicarbonate
in a study where all groups receive calcium and bicarbonate supplementation.
Disorders of glucose homeostasis affect approximately 50% of patients suffering from CKD [55,56],
which play a major role in mortality [57]. Pilot clinical studies demonstrated a potential impact of
VLPD + KAs compared to an LPD on insulin sensitivity in severe CKD patients [58,59]. However,
an LPD is able to improve insulin sensitivity and it is difficult to decipher if KAs have an additive
effect [60]. More recently, Teplan et al. have highlighted that, with a similar protein intake, KAs
supplementation was able to decrease glycated hemoglobin and visceral body fat, and improve lipid
metabolism [4].
Lastly, Di Iorio et al. reported that a VLPD+ KAs diet allowed for a long-lasting reduction of the
erythropoietin (EPO) dose required to maintain serum hemoglobin. In this study, the variation of EPO
dose directly correlated with the improvement in parathyroid hormone levels. This suggests that the
effect of KAs on anemia control was related to the control of phosphorus metabolism [31].
We strongly suggest that such research should be continued to better understand the mechanisms
involved during KAs diets. Better knowledge on the interaction between protein intake, gut microbiota,
and URS production offers new ways to analyze the mechanisms of action of KAs and increase the
motivation of physicians, dietitians, and patients for implementing this diet.
4. Do Ketoacid Analogues Have an Impact on Renal Function and Mortality in CKD?
The beneficial role of KAs supplementation on renal function is well established in experimental
models, but the effects are different in human clinical trials. LPD/VLPD + KAs were able to decrease
proteinuria, renal fibrosis, and severe glomerular sclerosis in different CKD rodent models, as disclosed
in Table 2 [9,10,13–15,17–19]. However, the majority of these preclinical studies have compared
a normal protein diet vs. VLPD/LPD + KAs. It is, therefore, difficult to decipher the specific effect of the
KAs supplementation [9,10,15,17–19]. Gao et al. highlighted that supplementation of KAs increased the
Kruppel-like factor-15, which is a transcription factor shown to reduce fibrosis in 5/6 nephrectomized
rats [14]. In this study, rats under LPD + KA had 1% less protein in their diet than rats under LPD but
this was likely not sufficient to explain the improvement in renal function. To demonstrate specific
effects of KAs, Zhang et al. [10] reported that mesangial cells treated with serum derived from 3/4
nephrectomized rats rapidly expressed higher expression of Angiotensin II and Angiotensin I receptors
compared to a serum obtained from sham rats. Serum from CKD rats fed LPD significantly inhibited
these abnormalities and this effect was even more pronounced with serum from CKD rats fed with
LPD + KAs, which suggests that KAs may be directly involved or respond to the greater decrease in
protein intake. This is a fact that limited the deleterious activation of renin-angiotensin system.
The interpretation of literature about the clinical efficacy of KAs seems controversial and depends
on the chosen inclusion criteria. A recent meta-analysis (n = 10 RCT, 1010 patients in CKD stage 4) in
non-diabetic CKD patients including the large positive study from Garneata et al. [21] and Milovanova
et al. [3] showed that VLPD reduced the number of patients reaching ESRD [61]. Another recent
meta-analysis with 661 patients, VLDP + KA significantly reversed the decrease of eGFR (mean
difference = 2.74, 95% confidence interval = (0.73, 4.75), p = 0.008) in CKD patients [62]. It should
be noted that, in the majority of these studies, protein intake was different between groups and the
selection of studies is questionable, which makes it difficult to interpret the true role of KAs.
The vast majority of RCTs testing VLPD + KAs reported a decrease in proteinuria. In the large
MDRD study, patients with proteinuria >3 g/24 h were more protected against CKD progression with
VLPD + KAs [35]. Garneata et al. did not observe a beneficial effect on proteinuria of a VLPD + KAs.
However, proteinuria was low in that particular study (<1 g/24 h) [21]. By contrast, in patients with
a proteinuria >1 g/24 h, a VLPD + KAs was able to significantly decrease proteinuria [20,52,63,64].
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It could be suggested that the anti-proteinuric effect of KAs is more important in patients with
a higher proteinuria.
Until now, there is no evidence that LPD/VLPD + KAs have an impact on patients’ survival.
A post hoc analysis of the MDRD study demonstrated a slightly increased mortality rate in the
VLPD + KAs group after 10 years of study completion (1.95: 95% CI; 1.15–3.20) [25]. However, in
this study, the diet adherence was not followed after the termination of the study, and there was
no information on the clinical survey and treatments of the patients. The Bellizzi’ historical cohort
with approximately 200 patients followed up for more than 10 years did not show adverse effects
and suggested possible greater survival [65]. Mortality of patients consuming VLPD + KAs was
8% patients/year, while, in the control group, it was 10% [65]. In another long-term observational
study (>10 year), Chauveau et al. did not observe a correlation between the death rate and duration
of diet [66]. In recent RCTs, no difference in death or cardiovascular events was observed [3,21].
It should be noted that these studies were not designed to answer this question and larger RCTs
are recommended.
5. Is a Keto Acid Analogues Supplementation a Modern Treatment?
There is some evidence about potential benefits of LPD/VLPD + KAs on renal outcomes but
the effects seem small and this questions its generalization compared to modern treatments such as
renin-angiotensin-aldosterone system (RAAS) inhibitors. In a recent review [67], we reported that
there was no clinical evidence for synergistic effects of the RAAS inhibitor and LPD. Experimental and
clinical studies evaluating the additive effect of an LPD and RAAS inhibition are few, of low quality and
limited duration, and only demonstrate significant beneficial effects on proteinuria. The recent study by
Garneata et al. in which 71% of participants were receiving an RAAS inhibitory treatment, showed that
the probability of worsening kidney function or need for dialysis was lower in the VLPD + KAs group
when adjusted for RAAS inhibitors (hazard ratio, 0.10, 95% CI, 0.05-0.20) [21]. Bellizi et al. studied 45%
of patients who were under RAAS inhibition and observed a 35% decrease in proteinuria under an
LPD and KA combination compared to a normal diet (vs. −1% in the free diet group) [65]. However,
in two recent RCTs, the use of RAAS inhibitors were not detailed or have low incidence [3,20].
The other major concern is a potential risk of malnutrition and kidney cachexia. The majority
of studies confirmed the safety of VLPD + KAs. In experimental models, the addition of Kas to the
LPD largely prevented the loss of weight and completely normalized serum albumin levels [13,14].
In the MDRD study, patients with protein restriction lost about 2 kg and showed a decrease in other
anthropometric parameters during the first four months only, likely because of reduced energy intake.
Biochemical and anthropometric indices of nutritional status were generally well within normal
limits during follow-up and at the end of the MDRD study [35]. In all RCTs testing VLPD + KAs
therapy with dietary management performed by trained dietitians reported no change in serum
albumin [5,21,26,29,30,33,68], which is subjective to the global assessment score [21,68] or BMI [33].
In recent meta-analyses, Hahn et al. [61] have reported that, among four studies comparing nutritional
measures with VLPD or LPD (n = 291), the mean final body weight was 1.4 kg higher with VLPD
when compared to LPD. Therefore, the risk for wasting during VLPD is 0.6%. This is a magnitude
that is not different from normal diets (0.4%). However, the specific role of Kas was not tested in this
study [61]. Using whole-body DEXA in an observational study, patients with VLPD + KAs showed
a significant decrease in lean tissue mass and an increase in total body fat. These different modifications
occurred abruptly during the first three months, and then stabilized or slightly improved thereafter [69].
In another cohort, after at least two years, muscle strength increased in CKD diabetic patients under
VLPD + KAs [70].
The routine use of VLPD + KAs in clinical practice remains challenging. Their benefits were
mainly seen in patients who showed good compliance to an LPD. The study of Garneata et al. was the
first study confirming this fact [21]. Only 14% of the screened patients were kept for the study and
randomized, which underlines the limitation to propose this therapy to a larger number of patients.
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Similarly, with a less reduced protein intake, Milovanova et al. included 33% of the screened patients [3].
Overall, only 30% of the pre-selected patients correctly achieved a VLPD + KAs [71]. Zoccali et al.
suggested that it is unrealistic to have, at a country level, about one-third of the whole workforce of
dietitians entirely dedicated to the follow-up of CKD patients [72].
Another key question is whether LPD/VLPD + KAs is applicable to the elderly patients who
presently dominate the CKD population but are less likely to be recruited into RCTs. Elderly patients
have already spontaneous lower dietary protein intakes and are developing sarcopenia. Cognitive
deficit may also challenge an effective and safe follow-up of such restricted diets. The RCT Diet or
Dialysis in Elderly (DODE) trial, which included 112 patients [73], observed that VLPD + KAs was an
efficient strategy to delay the need for dialysis. The interpretation of this study is not consensual and it
seems that VLPD + KAs might have increased recurring episodes of fluid overload or hyperkalemia [74].
However, the mortality rate was not different between the two groups and the hospitalization rate was
higher in the dialysis group.
If some preliminary data suggest that VLPD + KAs supplementation is interesting and safe
in dialysis patients, after renal transplantation or during pregnancy in CKD women, further large
studies are necessary [75,76]. Lastly, the best timing, e.g., the kidney disease stage to start a KA
supplementation, has not been clearly defined.
A final question is: what are the optimal level and composition of KAs that are needed? One
observational study showed that a low dose of KAs had a beneficial effect to slow down renal
function deterioration in pre-dialysis patients [77]. Some studies suggest that amino acid like lysine
supplementation may improve vascular calcification [78]. By contrast, tryptophan and tyrosine
are precursors of URS and, therefore, may be deleterious. As mentioned above, the role of BCAA
supplementation must also be clarified.
6. Conclusion
The results of this review support the beneficial effects of VLDP + KAs in CKD patients on
renal function and different metabolic parameters in particular acidosis, insulin resistance, and bone
metabolism without alteration of the nutritional status. However, evidence is inconclusive regarding
the effect of VLDP + KA on mortality and cardiovascular events. The recommendation for the use
of KAs has not reached consensus and remains a second-choice alternative. Few international and
national societies currently recommend KAs supplementation in the management of CKD (Table 4).
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Table 4. VLDP/LDP and KA in non-dialyzed patients with chronic kidney disease.
CKD
Stage
NKF/KDOQI Clinical Practice
Guidelines for Nutrition in
Chronic Renal Failure, 2000 [79]
ESPEN Guidelines on
Enteral Nutrition: Adult
Renal Failure, 2006 [80]
Australian KHA-CARI
Guidelines [81] KDIGO, 2012 [82]
International Society of
Renal Nutrition and
Metabolism, 2013 [83]
Review, 2017, NEJM [84]
3 0.60–0.75 g/kg/day of protein 0.55–0.6 g/kg/day of protein 0.75–1.0 g/kg/day of protein <1.3 g/kg/day protein 0.6 and 0.8 g/kg/day protein,≥50% of protein of HBV
<1.0 g/kg/day protein (consider
0.6–0.8 if eGFR <45 mL/min/1.73 m2
or rapid progression)
4–5 0.60–0.75 g/kg/day of protein
0.55–0.6 g/kg/day of protein
(2/3 HBV) or ~0.3 g/kg/day of
protein supplemented with
KAs/EAAs (0.1 g/kg/day)
0.75–1.0 g/kg/day 0.8 g/kg/day protein 0.6 and 0.8 g/kg/day protein,≥50% of protein of HBV
0.6–0.8 g/kg/day protein, including
50% HBV protein, or <0.6 with
addition of EAAs or KAs
(0.1 g/kg/day)
HBV: high biological value. KAs: ketoacids analogues. EAAs: essential amino acids.
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7. Future Directions
The low adherence is a main caveat when prescribing VLPD + KAs. Ethnic and cultural dietary
variations between CKD populations raise the question of whether the results of protein restriction trials
are applicable on an international basis. Another limitation is the side effects of KAs. They can induce
hypercalcemic episodes due to their calcium content and uncomfortable gastrointestinal symptoms.
In a developing country without easy access of the medical resource, as compared with the maintenance
dialysis expenses, the low cost of KAs may be an attractive alternative strategy. Considering an average
yearly cost of about 34,072 € for dialysis and 1440 € for the diet, treating patients with VLDP + KA
and delaying dialysis treatment would allow significant financial savings [85]. In Western countries,
VLPD + KAs may be proposed as a possible tool to reduce CKD costs and postpone dialysis when
waiting for fistula maturation or for a living kidney transplant. The personalized medicine is one of the
emerging clinical models in the new millennium. Additionally, multiple choice regarding diet linked
to patient characteristics may lead to better adherence [86]. Further studies are needed to identify
factors that influence patient adherence. Incremental dialysis, which combines a nutritional-dialysis
approach, may be an option for avoiding the abrupt start of thrice weekly hemodialysis and should be
one of the possible new treatment options. Additionally, further research will be required to establish
the optimal KAs dose and role of this diet on uremic toxin production.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/9/2071/s1.
Figure S1: Identification process for randomized clinical studies.
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